Final Glance: Biotechnology companies
AP - Tue Aug 12, 5:11PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
UBS AG Contemplates $4.5B Bond Offerings in U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 4:05PM CDT
As per Bloomberg, the Swiss major UBS AG (UBS) is planning corporate bond offerings in the U.S. The bank will be issuing $4.5 billion worth of bonds.
Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
PR Newswire Europe - Tue Aug 12, 12:50PM CDT
DUBLIN, Aug. 12, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/kpr76z/biological_drugs] has announced the addition of the "Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" [http://www.researchandmarkets.com/research/kpr76z/biological_drugs] report to their offering.
Midday Glance: Biotechnology companies
AP - Tue Aug 12, 12:47PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Aug 12, 11:14AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Amgen Up 8.6% Since SmarTrend Uptrend Call (AMGN)
Comtex SmarTrend(R) - Tue Aug 12, 9:27AM CDT
SmarTrend identified an Uptrend for Amgen (NASDAQ:AMGN) on June 2nd, 2014 at $116.45. In approximately 2 months, Amgen has returned 8.57% as of today's recent price of $126.43.
5 Things Amgen, Inc.'s Management Wants You to Know
Sean Williams, The Motley Fool - Motley Fool - Mon Aug 11, 3:25PM CDT
Amgen reported its second-quarter earnings results two weeks ago, delivering yet another quarter of impressive growth and boosting full-year guidance. Source: University of Michigan School of Natural Resources & Environment , Flickr. ...
Investors Applaud Amgen and Novartis for Support of Investor Principles on Biosimilars, Alternatives to Higher Cost Drugs
PR Newswire - Mon Aug 11, 12:07PM CDT
A coalition of 19 institutional investors representing $430 billion in assets commends Amgen and Novartis for support of a set of investor principles to guide corporate boards on policy and oversight responsibilities related to biosimilar activities. The principles, included in the coalition's Investor Statement on Board Oversight of Biosimilar Issues, call on boards to ensure that information provided to policymakers on patient safety is balanced, investor dollars used for political lobbying is aligned with shareholder interests, and disclosure on significant business partnerships is transparent. Biosimilars are biologic medical products whose active drug substance is derived from a living organism and used to treat serious illnesses including cancer, rheumatoid arthritis, and multiple sclerosis.
Earnings Flashback: Since Reporting Quarterly Results 1 Week Ago Amgen Is Up 3.0% (AMGN)
Comtex SmarTrend(R) - Mon Aug 11, 12:02PM CDT
A week ago on July 29th, 2014 Amgen (NASDAQ:AMGN) reported earnings and analysts, on average, expected earnings of $2.07 on sales of $4.9 billion. The company actually reported EPS of $2.37 on sales of $5.2 billion, beating EPS estimates by $0.30 and beating revenue estimates by $279.7 million. Shares of Amgen have climbed from $123.31 to $126.95, representing a gain of 3.0% since the company reported earnings 13 days ago.
Amgen Receives CEO Cancer Gold Standard Accreditation
Business Wire - Mon Aug 11, 6:00AM CDT
The CEO Roundtable on Cancer today announced that Amgen, Inc., one of the world's leading biotechnology companies, has received CEO Cancer Gold Standard(TM) accreditation. This achievement recognizes employers' commitment to reducing cancer risk by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring access to quality treatment for employees and covered family members.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Aug 08, 7:15PM CDT
Cramer's watching earnings next week as he seeks stocks worth buying, not selling, in this market.
3 Biotech Stocks to End Q2 on a Winning Note - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 2:54PM CDT
The rebound was due to strong earnings reports, product approvals, and acquisitions and licensing deals.
Critical Alerts For Stratasys, Horizon Pharma, Isis Pharmaceuticals, Amgen, and Discover Financial Services Released By InvestorsObserver
PR Newswire - Fri Aug 08, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SSYS, HZNP, ISIS, AMGN, and DFS.
Look for Shares of Amgen to Potentially Rebound after Yesterday's 1.05% Sell Off
Comtex SmarTrend(R) - Thu Aug 07, 3:42PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $125.51 to a high of $128.89. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $126.52 on volume of 3.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Amgen Set to Possibly Rebound After Yesterday's Selloff of 1.05%
Comtex SmarTrend(R) - Thu Aug 07, 3:42PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $125.51 to a high of $128.89. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $126.52 on volume of 3.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.